Pap test pioneers stake out growth opportunities
This article was originally published in Clinica
Executive Summary
Cytyc, the market leader in the new generation of Pap tests, reported strong results in the third quarter, while its much smaller rival, TriPath Imaging, admitted that it had over-estimated its likely sales for 2004. However, TriPath is finding room for expansion in markets that are dominated by Cytyc, and the latter has had to look beyond disposable test and instrument revenues for its future growth strategy.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.